(CPHI)

China Pharma Holdings, Inc.

Close Price:
0.76

Change:
0.02 Stock Price Increase0.02

% Change:
0.027027027027027027027027027 Stock Price Increase2.70 %

Date:
2/1/2012

52 Week:
0.62 - 3.10

Prev Close:
0.74

Open:
0.76

Volume:
54,800

90D Avg. Volume:
82,226

2/1/2012 Range:
0.75 - 0.76

Market Cap:
33,082,800

Trailing PE Ratio:
1.65

Shares Out:
43,530,000

EPS:
0.46

Yield:
0.00

Dividend:
0.00

Dividend Date:
-

Quarter End:
3/31/2012

China Pharma Holdings, Inc.

Sector: Healthcare

Industry: Drug Manufacturers - Major

Website: www.chinapharmaholdings.com

Business Summary: China Pharma Holdings, Inc. develops, manufactures, and markets generic and branded pharmaceutical products primarily to hospitals and private retailers in the People?s Republic of China. Its products include Bumetanide to treat edema diseases; Gastrodin injection for tiredness, loss of concentration, poor sleep, and traumatic syndromes of brain; Cerebroprotein Hydroloysate injection for the treatment of memory decline and attention deficit; Buflomedil Hydrochloride for blood vessel diseases; Propylgallate and Ozagrel Sodium for the treatment of cerebral thrombosis, coronary heart disease, and thrombus deep phlebitis; and Alginic Sodium Diester injection for ischemic heart, cerebrovascular, and lipoprotein blood diseases. The company also offers Cefaclor Dispersible tablets for tympanitis, lower respiratory tract, urinary tract, and skin/skin tissue infection; Roxithromycin dispersible tablets for pharyngitis and tonsillitis; Clarithromycin granules and capsules for nasopharynx, respiratory tract, and skin tissue infections; Naproxen Sodium and Pseudophedrine Hydrochloride Sustained Release tablets to relieve cold, sinus, and flu symptoms; Cefalexin capsules for acute tonsillitis; and Anhydroandrographolide for ischemic heart, cerebrovascular, and lipoprotein blood diseases. In addition, it provides Hepatocyte growth-promoting factor to treat viral hepatitis symptoms; Tiopronin to treat acute chronic Hepatitis B and relieve liver injury; Omeprazole to treat gastroesophageal reflux disease; Granisetron Hydrochloride injection for nausea and vomiting; Vitamin B6, an vitamin supplement; Thymopolypetides injection for treating diseases and tumors of various cells with reduced immunological function; and Recombined Human Fibroblast Growth Factor for the production of cosmetics. The company distributes its products through independent regional distributors and sales representatives. China Pharma Holdings, Inc. is based in Haikou, the People?s Republic of China.


Jinpan Road
No.17
Haikou, 570216 China ,
P: 86 898 6681 1730
F: 86 898 6681 9024

CPHI Earnings Calendar

Q1:
Jan
1
 -
Mar
31
Q2:
Apr
1
 -
Jun
30
Q3:
Jul
1
 -
Sep
30
Q4:
Oct
1
 -
Dec
31
Period Ending
 
Assets
Current Assets
Cash & Cash Equivalents
Short Term Investments
Net Receivables
Inventory
Other Current Assets
Total Current Assets
Long Term Assets
Property Plant & Equipment
Goodwill
Intangible Assets
Accumulated Amortization
Other Assets
Deferred Long Asset Charges
Total Assets
Liabilities
Current Liabilities
Accounts Payable
Short/Current Long Term Debt
Other Current Liabilities
Total Current Liabilities
Long Term Debt
Other Liabilities
Deferred Long Term Liability Charges
Minority Interest
Negative Goodwill
Total Liabilities
Stockholders' Equity
Misc Stock Options Warrants
Redeemable Preferred Stock
Preferred Stock
Common Stock
Retained Earnings
Treasury Stock
Capital Surplus
Other Stockholder Equity
Total Stockholder Equity
Net Tangible Assets
12/31/2009
 
 
 
$3,635
$0
$53,435
$14,233
$0
$71,303
$0
$6,706
$0
$19,332
$0
$3,600
$0
$100,941
 
 
$6,706
$3,803
$0
$10,508
$37
$0
$0
$0
$0
$10,545
 
$0
$0
$0
$42
$0
$0
$21,178
$5,903
$90,396
$71,064
  
 
 
 
  
  
  
  
  
  
  
  
  
  
  
  
  
  
 
 
  
  
  
  
  
  
  
  
  
  
 
  
  
  
  
  
  
  
  
  
  
YoY
 
 
 
(47.5%)
0.0%
34.7%
8.3%
0.0%
19.4%
(100.0%)
(0.5%)
0.0%
213.7%
0.0%
0.0%
0.0%
33.7%
 
 
117.2%
53.3%
0.0%
88.8%
0.0%
(100.0%)
0.0%
0.0%
0.0%
88.2%
 
0.0%
0.0%
0.0%
0.0%
0.0%
0.0%
0.5%
3.2%
29.4%
11.5%
  
 
 
 
  
  
  
  
  
  
  
  
  
  
  
  
  
  
 
 
  
  
  
  
  
  
  
  
  
  
 
  
  
  
  
  
  
  
  
  
  
12/31/2008
 
 
 
$6,927
$0
$39,665
$13,140
$0
$59,732
$2,839
$6,738
$0
$6,163
$0
$0
$0
$75,472
 
 
$3,087
$2,480
$0
$5,567
$0
$36
$0
$0
$0
$5,604
 
$0
$0
$0
$42
$0
$0
$21,066
$5,720
$69,868
$63,706
  
 
 
 
  
  
  
  
  
  
  
  
  
  
  
  
  
  
 
 
  
  
  
  
  
  
  
  
  
  
 
  
  
  
  
  
  
  
  
  
  
YoY
 
 
 
278.5%
0.0%
75.9%
(9.1%)
0.0%
53.8%
0.0%
156.7%
0.0%
198.7%
0.0%
0.0%
(100.0%)
72.7%
 
 
153.7%
(7.9%)
0.0%
42.3%
0.0%
5.9%
0.0%
0.0%
0.0%
42.1%
 
0.0%
0.0%
0.0%
13.5%
0.0%
0.0%
80.4%
101.5%
75.7%
69.0%
  
 
 
 
  
  
  
  
  
  
  
  
  
  
  
  
  
  
 
 
  
  
  
  
  
  
  
  
  
  
 
  
  
  
  
  
  
  
  
  
  
Period Ending
 
Assets
Current Assets
Cash & Cash Equivalents
Short Term Investments
Net Receivables
Inventory
Other Current Assets
Total Current Assets
Long Term Assets
Property Plant & Equipment
Goodwill
Intangible Assets
Accumulated Amortization
Other Assets
Deferred Long Asset Charges
Total Assets
Liabilities
Current Liabilities
Accounts Payable
Short/Current Long Term Debt
Other Current Liabilities
Total Current Liabilities
Long Term Debt
Other Liabilities
Deferred Long Term Liability Charges
Minority Interest
Negative Goodwill
Total Liabilities
Stockholders' Equity
Misc Stock Options Warrants
Redeemable Preferred Stock
Preferred Stock
Common Stock
Retained Earnings
Treasury Stock
Capital Surplus
Other Stockholder Equity
Total Stockholder Equity
Net Tangible Assets
12/31/2009
 
 
 
$3,635
$0
$53,435
$14,233
$0
$71,303
$0
$6,706
$0
$19,332
$0
$3,600
$0
$100,941
 
 
$6,706
$3,803
$0
$10,508
$37
$0
$0
$0
$0
$10,545
 
$0
$0
$0
$42
$0
$0
$21,178
$5,903
$90,396
$71,064
  
 
 
 
  
  
  
  
  
  
  
  
  
  
  
  
  
  
 
 
  
  
  
  
  
  
  
  
  
  
 
  
  
  
  
  
  
  
  
  
  
QoQ
 
 
 
(47.5%)
0.0%
34.7%
8.3%
0.0%
19.4%
(100.0%)
(0.5%)
0.0%
213.7%
0.0%
0.0%
0.0%
33.7%
 
 
117.2%
53.3%
0.0%
88.8%
0.0%
(100.0%)
0.0%
0.0%
0.0%
88.2%
 
0.0%
0.0%
0.0%
0.0%
0.0%
0.0%
0.5%
3.2%
29.4%
11.5%
  
 
 
 
  
  
  
  
  
  
  
  
  
  
  
  
  
  
 
 
  
  
  
  
  
  
  
  
  
  
 
  
  
  
  
  
  
  
  
  
  
9/30/2009
 
 
 
$3,845
$0
$51,254
$14,916
$0
$70,014
$0
$6,872
$0
$18,422
$0
$0
$0
$95,309
 
 
$6,296
$3,803
$0
$10,098
$37
$0
$0
$0
$0
$10,135
 
$0
$0
$0
$42
$0
$0
$21,066
$5,899
$85,174
$66,752
  
 
 
 
  
  
  
  
  
  
  
  
  
  
  
  
  
  
 
 
  
  
  
  
  
  
  
  
  
  
 
  
  
  
  
  
  
  
  
  
  
6/30/2009
 
 
 
$3,643
$0
$45,855
$14,874
$0
$64,372
$6,656
$6,756
$0
$14,801
$0
$0
$0
$85,929
 
 
$5,483
$2,484
$0
$7,967
$0
$37
$0
$0
$0
$8,004
 
$0
$0
$0
$42
$0
$0
$21,066
$5,813
$77,925
$63,124
  
 
 
 
  
  
  
  
  
  
  
  
  
  
  
  
  
  
 
 
  
  
  
  
  
  
  
  
  
  
 
  
  
  
  
  
  
  
  
  
  
Period Ending
Net Income
Operating Activities
Depreciation
Adjustments To Net Income
Changes In Accounts Receivables
Changes In Liabilities
Changes In Inventories
Changes In Other Operating Activities
Total from Operating Activities
Investing Activities
Capital Expenditures
Investments
Other Investing Activities
Total from Investing Activities
Financing Activities
Dividends Paid
Sale Purchase of Stock
Net Borrowings
Other Financing Activites
Total from Financing Activities
Effect of Exchange Rate Changes
Change in Cash and Cash Equivalents
12/31/2009
$20,233
 
$1,369
($1,632)
($11,990)
$3,749
($1,060)
$0
$10,669
 
($143)
$0
($15,218)
($15,361)
 
$0
$70
$1,316
$0
$1,386
$14
($3,292)
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
YoY
13.5%
 
90.4%
(1,416.1%)
23.9%
129.6%
(147.3%)
100.0%
63.1%
 
96.7%
100.0%
(263.7%)
(47.1%)
 
0.0%
(99.2%)
439.2%
0.0%
(84.4%)
(87.7%)
(164.6%)
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
12/31/2008
$17,834
 
$719
$124
($15,753)
$1,633
$2,243
($257)
$6,543
 
($4,311)
($1,946)
($4,184)
($10,441)
 
$0
$9,269
($388)
$0
$8,881
$114
$5,097
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
YoY
39.1%
 
70.4%
121.3%
(140.4%)
1,238.5%
167.4%
(152.0%)
133.5%
 
(8,190.4%)
0.0%
(193.0%)
(605.5%)
 
0.0%
136.7%
90.6%
0.0%
4,474.9%
107.3%
334.2%
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Period Ending
Net Income
Operating Activities
Depreciation
Adjustments To Net Income
Changes In Accounts Receivables
Changes In Liabilities
Changes In Inventories
Changes In Other Operating Activities
Total from Operating Activities
Investing Activities
Capital Expenditures
Investments
Other Investing Activities
Total from Investing Activities
Financing Activities
Dividends Paid
Sale Purchase of Stock
Net Borrowings
Other Financing Activites
Total from Financing Activities
Effect of Exchange Rate Changes
Change in Cash and Cash Equivalents
12/31/2009
$5,106
 
$383
$255
($2,397)
$252
$683
$0
$4,281
 
$112
$0
($4,674)
($4,562)
 
$0
$70
$0
$0
$70
$1
($210)
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
QoQ
(4.6%)
 
79.0%
6,275.0%
52.4%
(61.0%)
(50.8%)
100.0%
70.1%
 
102.7%
100.0%
(322.5%)
(13.2%)
 
0.0%
0.0%
(100.0%)
0.0%
(97.1%)
(99.4%)
(119.3%)
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
9/30/2009
$7,163
 
$427
($1,772)
($3,572)
$1,105
($26)
$116
$3,326
 
$3,791
$0
($8,235)
($4,443)
 
$0
$0
$1,315
$0
$1,315
$4
$202
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
6/30/2009
$4,286
 
$301
($116)
($2,193)
$1,211
($1,667)
$123
$1,945
 
($3,523)
$0
$68
($3,455)
 
$0
$0
$0
$0
$0
$2
($1,509)
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Period Ending
Total Revenue
Cost of Revenue
Gross Profit
Operating Expenses
Research Development
Selling General & Administrative
Non Recurring
Others
Total Operating Expenses
Operating Income or Loss
Income from Continuing Operations
Total Other Income/Expenses Net
Earnings Before Interest And Taxes
Interest Expense
Income Before Tax
Income Tax Expense
Minority Interest
Net Income From Continuing Ops
 
Non-recurring Events
Discontinued Operations
Extraordinary Items
Effect Of Accounting Changes
Other Items
Net Income
Preferred Stock And Other Adjustments
Net Income Applicable To Common Shares
12/31/2010
$74,388
$44,105
$30,283
 
$0
$5,113
$505
$0
$0
$24,665
 
$1,604
$26,269
$168
$26,101
$2,686
$0
$23,414
 
 
$0
$0
$0
$0
$23,414
$0
$23,414
  
  
  
  
 
  
  
  
  
  
  
 
  
  
  
  
  
  
  
 
 
  
  
  
  
  
  
  
YoY
20.6%
22.4%
18.1%
 
0.0%
5.4%
127.8%
0.0%
0.0%
9.1%
 
172.1%
28.8%
9.1%
29.0%
18.7%
0.0%
30.3%
 
 
0.0%
0.0%
0.0%
0.0%
30.3%
0.0%
30.3%
  
  
  
  
 
  
  
  
  
  
  
 
  
  
  
  
  
  
  
 
 
  
  
  
  
  
  
  
12/31/2009
$61,697
$36,046
$25,650
 
$0
$4,853
($1,817)
$0
$0
$22,615
 
($2,225)
$20,389
$154
$20,235
$2,262
$0
$17,973
 
 
$0
$0
$0
$0
$17,973
$0
$17,973
  
  
  
  
 
  
  
  
  
  
  
 
  
  
  
  
  
  
  
 
 
  
  
  
  
  
  
  
YoY
21.0%
40.4%
1.4%
 
0.0%
30.7%
0.0%
(100.0%)
0.0%
14.6%
 
(3,736.2%)
3.6%
17.6%
3.6%
32.4%
0.0%
0.8%
 
 
0.0%
0.0%
0.0%
0.0%
0.8%
0.0%
0.8%
  
  
  
  
 
  
  
  
  
  
  
 
  
  
  
  
  
  
  
 
 
  
  
  
  
  
  
  
Period Ending
Total Revenue
Cost of Revenue
Gross Profit
Operating Expenses
Research Development
Selling General & Administrative
Non Recurring
Others
Total Operating Expenses
Operating Income or Loss
Income from Continuing Operations
Total Other Income/Expenses Net
Earnings Before Interest And Taxes
Interest Expense
Income Before Tax
Income Tax Expense
Minority Interest
Net Income From Continuing Ops
 
Non-recurring Events
Discontinued Operations
Extraordinary Items
Effect Of Accounting Changes
Other Items
Net Income
Preferred Stock And Other Adjustments
Net Income Applicable To Common Shares
12/31/2010
$23,974
$14,494
$9,479
 
$0
$1,504
$290
$0
$0
$7,686
 
$1,591
$9,277
$28
$9,248
$890
$0
$8,359
 
 
$0
$0
$0
$0
$8,359
$0
$8,359
  
  
  
  
 
  
  
  
  
  
  
 
  
  
  
  
  
  
  
 
 
  
  
  
  
  
  
  
QoQ
22.4%
17.6%
30.6%
 
0.0%
18.0%
1.8%
0.0%
0.0%
34.9%
 
170.7%
169.1%
(45.1%)
172.3%
61.8%
0.0%
193.7%
 
 
0.0%
0.0%
0.0%
0.0%
193.7%
0.0%
193.7%
  
  
  
  
 
  
  
  
  
  
  
 
  
  
  
  
  
  
  
 
 
  
  
  
  
  
  
  
9/30/2010
$18,680
$11,055
$7,625
 
$0
$857
$107
$0
$0
$6,661
 
($465)
$6,197
$38
$6,159
$674
$0
$5,485
 
 
$0
$0
$0
$0
$5,485
$0
$5,485
  
  
  
  
 
  
  
  
  
  
  
 
  
  
  
  
  
  
  
 
 
  
  
  
  
  
  
  
QoQ
20.3%
23.1%
16.5%
 
0.0%
(35.5%)
103.8%
100.0%
0.0%
(17.3%)
 
(11,725.0%)
(23.1%)
58.3%
(23.3%)
(22.4%)
0.0%
(23.4%)
 
 
0.0%
0.0%
0.0%
0.0%
(23.4%)
0.0%
(23.4%)